Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule

2012 ◽  
Vol 126 (2) ◽  
pp. 211-216 ◽  
Author(s):  
Takafumi Toita ◽  
Ryo Kitagawa ◽  
Tetsutaro Hamano ◽  
Kenji Umayahara ◽  
Yasuyuki Hirashima ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Concurrent Chemoradiotherapy ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Dose Schedule ◽  
Uterine Cervical Cancer ◽  
High Dose Rate ◽  
Intracavitary Brachytherapy ◽  
High Dose ◽  
Cumulative Radiation Dose

Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer

2005 ◽  
Vol 96 (3) ◽  
pp. 665-670 ◽  
Author(s):  
Takafumi Toita ◽  
Hidehiko Moromizato ◽  
Kazuhiko Ogawa ◽  
Yasumasa Kakinohana ◽  
Toshiyuki Maehama ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dose Rate ◽  
Concurrent Chemoradiotherapy ◽  
Uterine Cervical Cancer ◽  
High Dose Rate ◽  
Intracavitary Brachytherapy ◽  
High Dose

Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy with a modified dose schedule: Retrospective analysis of a single institutional experience

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15019-15019
Author(s):  
T. Toita ◽  
W. Tamaki ◽  
T. Maehama ◽  
K. Ogawa ◽  
Y. Nagai ◽  
...  
Keyword(s):  
Survival Rate ◽  
Dose Rate ◽  
Retrospective Analysis ◽  
Concurrent Chemoradiotherapy ◽  
Dose Schedule ◽  
High Dose Rate ◽  
Late Complications ◽  
Intracavitary Brachytherapy ◽  
High Dose ◽  
Minimum Diameter

15019 Background: The purpose of this study was to assess the effectiveness of concurrent chemoradiotherapy (CCRT) using high-dose-rate intracavitary brachytherapy (HDR-ICBT) with a dose schedule modified from the American Brachytherapy Society (ABS) recommendation. Methods: 68 consecutive patients (IB2: 3, IIA: 2, IIB: 32, and IIIB: 31) with cervical squamous cell carcinoma consecutively treated with CCRT using HDR-ICBT were retrospectively analyzed. Patients with para-aortic lymphadenopathy (greater than 10mm in minimum diameter assessed by CT) were excluded. The median tumor size (assessed by MRI) was 60mm (range: 40–86mm). Cisplatin (20 mg/m2/day) was concurrently administered with radiotherapy (RT) for 5 days at 21-day intervals for a median of 2 courses (range: 1–5). The planned RT schedule consisted of pelvic external beam RT (EBRT) with 40Gy/20 fractions followed by HDR-ICBT with 18Gy/3 fractions and pelvic EBRT with 10Gy/5 fractions using a midline block (MB). The cumulative biologically effective dose (BED) at point A of this schedule was 77Gy10. 60 patients (88%) were treated with this schedule. In the remaining 8 patients, pelvic EBRT was delivered without MB (up to 50Gy), and/or additional HDR-ICBT (up to 24Gy) was given. The actual BED for all 68 patients thus ranged from 77 to 89 Gy10. Median follow-up of the surviving 54 patients was 46 months (range: 8–91 months). Late complications were graded by the RTOG/EORTC criteria. Results: The actuarial overall survival rate, disease-free survival rate, and pelvic control rate at 4 years were 78% (95% CI, 68–90%), 74% (95% CI, 63–85%), and 90% (95% CI, 83–97%), respectively. Only one patient suffered a grade 3 complication (enterocolitis). The actuarial late complication (Grade 1or higher) rates at 4 years were 12% (95% CI, 3–20%) for proctitis, 2% (95% CI, 0–5%) for cystitis, and 21% (95% CI, 10–33%) for enterocolitis. Conclusions: This retrospective analysis suggests that CCRT using HDR-ICBT with a modified dose schedule was able to achieve favorable pelvic disease control without severe late complications for patients with cervical cancer. No significant financial relationships to disclose.

Phase II study of concurrent chemoradiotherapy with weekly CDDP/PTX in patients with locally advanced uterine cervical cancer: JACCRO-GY-01 trial.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 5587-5587
Author(s):  
Munetaka Takekuma ◽  
Yasuyuki Hirashima ◽  
Kenji Umayahara ◽  
Shin-ei Noda ◽  
Tatsuya Ohno ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Concurrent Chemoradiotherapy ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Uterine Cervical Cancer
Sign in / Sign up

Export Citation Format

Share Document